Table 5 Patients and tumor characteristics of the selected studies Melanoma and Immunotherapy
From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Authors (year of publication) [reference] | N of pts underwent SBRT | Type of study | Primary tumor | N of mts underwent to SBRT | Type of Oligometases and organ involved | Median total dose per fraction | BED | Systemic Therapy | Mts size (cm), median |
|---|---|---|---|---|---|---|---|---|---|
Gabani 2018 [35] | 77 (288 received RT generically) | retrospective | Melanoma | Extracranial (bone, soft tissues, lung..) | 30 Gy (5fx) | Ipi, Pembro, Nivo, Il-2, Vaccines | N/A | ||
Stera 2018 [36] | 48a (35 received ICI) | retrospective | Melanoma | 250 | Brain, Extracranial (32pts.) | 18 Gy | BED10 50.4 Gy | ICI, BRAFi | 0.23 cm3 (per lesion) |
Liniker 2016 [37] | 35 | retrospective | Melanoma | Brain or Extracranial | Anti-PD1 | ||||
Qin 2015 [32] | 21 | retrospective | Melanoma | N.S. | Brain | Ipi | |||
Diao 2018 [33] | 51b | retrospective | Melanoma | 155 | Brain | 20 Gy | Ipi | 0.27 cm3 | |
Anderson 2017 [34] | 18 (11 SRS + 7 hypoRT) | retrospective | Melanoma | 23 | Brain | 20 Gy (1) < 2 cm; 18 Gy(1) < 3 cm; 30Gy(5) > 3 cm | Pembro | 1 cm (SRS) | |
Chen 2017 [15] | 260 (70 melanoma pts.d.) | retrospective | NSCLC, RCC, Melanoma | 623 (total) | Brain | 20 Gy | Anti PD-1, Anti Ctla4 | ||
Chandra 2015 [38] | 47c | retrospective | melanoma | 18 | Brain | 20Gy | 4 cm |